Janssen and Stop TB Partnership are to expand access to tuberculosis medicines under the terms of a new agreement.
The public-private partnership will facilitate access to tuberculosis therapies in over 130 low and middle-income countries outside of the US.
The novel collaboration has been agreed with the Stichting International Dispensary Association (IDA), a procurement agent for the Stop TB Partnership’s Global Drug Facility (GDF), to facilitate access to a new anti-tuberculosis medicine from Janssen.
A number of poorer countries outside of the US will then be able to obtain the medication through a procurement practice established by the GDF and IDA.
The partnership was established by the newly-formed Janssen Global Public Health as part of their efforts to improve public wellbeing.
Dr Paul Stoffels, chief scientific officer of parent company Johnson and Johnson and worldwide chairman of Janssen, said: “Multidrug-resistant tuberculosis is a complex public health problem. We feel we have a responsibility to work together with others in the tuberculosis community in order to tackle this challenge.”